B-cell malignancies

Is This Gilead Sciences' Most Underappreciated Drug Candidate?
Motley Fool
Mon, 07/18/16 - 10:59 am
Gilead Sciences
ONO/GS-4059
B-cell malignancies
Novartis jumps into bi-specific antibody space with $150 million Xencor deal
BioPharma Dive
Tue, 06/28/16 - 11:14 am
Novartis
bispecific antibodies
Xencor
acute myeloid leukemia
B-cell malignancies
Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability
Yahoo
Sun, 06/5/16 - 11:48 am
Juno Therapeutics
CD19
CAR-T
ASCO 2016
B-cell malignancies